Pacific Edge Limited
Research Pacific Edge Limited (PEB.AX) on Bullrun: market cap AUD 235.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPEB.AX
- ExchangeAU
- CountryNew Zealand
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyAUD
- Market capAUD 235.96M
- Financial periodFY2026
- RevenueNZD 11.50M
- Revenue growth-47.4%
- Net income-NZD 35.78M
- Free cash flow-NZD 32.07M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 235.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | NZD 11.50M | -NZD 35.78M | -NZD 32.07M | 100.0% | -0.04 | NZD 7.78M | NZD 1.29M | NZD 10.66M |
| FY2025 | NZD 21.85M | -NZD 29.94M | -NZD 26.01M | 100.0% | -0.04 | NZD 22.57M | NZD 2.90M | NZD 26.09M |
| FY2024 | NZD 23.91M | -NZD 29.54M | -NZD 27.12M | 100.0% | -0.04 | NZD 50.26M | NZD 4.07M | NZD 54.62M |
| FY2023 | NZD 19.62M | -NZD 26.97M | -NZD 28.48M | 100.0% | -0.03 | NZD 77.79M | NZD 1.22M | NZD 82.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 235.96M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pacific Edge Limited's market cap?
Pacific Edge Limited's market capitalization is AUD 235.96M.
What does Pacific Edge Limited do?
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer.